HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use VYNDAQEL and VYNDAMAX safely and effectively. See full prescribing information for VYNDAQEL and VYNDAMAX. VYNDAQEL® (tafamidis meglumine) capsules, for oral administration Initial U.S. Approval: 2019 VYNDAMAX™ (tafamidis) capsules, for oral administration Initial U.S. Approval: 2019 INDICATIONS AND USAGEVYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. (1) DOSAGE AND ADMINISTRATIONDOSAGE FORMS AND STRENGTHSCapsules: Tafamidis meglumine 20 mg and tafamidis 61 mg. (3) CONTRAINDICATIONSNone. (4) ADVERSE REACTIONSTo report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. (5) USE IN SPECIFIC POPULATIONSSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 6/2021 |
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
VYNDAQEL® OR VYNDAMAX™ Highlights (tafamidis meglumine or tafamidis)
Did you find an answer to your question?
Yes
No
Resources
Report Adverse Event
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at https://vaers.hhs.gov or call (800) 822-7967.